Received 28 August 2008
aDepartment of Neurosurgery, Third Affiliated Hospital of Soochow University, Changzhou 213003, People's Republic of China, and bLaboratory of Neuronal Injury and Protection, Third Affiliated Hospital of Soochow University, Changzhou 213003, People's Republic of China
Correspondence e-mail: firstname.lastname@example.org, email@example.com
The title compound, C10H10N2O, known as Edaravone (MCI-186), was crystallized from methanol. The two independent molecules in the asymmetric unit are linked through an O-HO hydrogen bond. One molecule adopts a ketone form, while the other adopts an enol form. In the crystal structure, molecules are linked through intermolecular N-HO hydrogen bonds, forming chains running along the b axis.
Data collection: SMART (Bruker, 2002); cell refinement: SAINT (Bruker, 2002); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: SHELXTL (Sheldrick, 2008); software used to prepare material for publication: SHELXL97.
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: SG2259 ).
Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (1987). J. Chem. Soc. Perkin Trans. 2, pp. S1-19.
Bruker (2002). SAINT and SMART. Bruker AXS Inc., Madison, Wisconsin, USA.
Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
The Edaravone Acute Infarction Study Group (2003). Cerebrovasc. Dis. 15, 222-229.
Watanabe, T., Yuki, S., Egawa, M. & Nishi, H. (1994). J. Pharmacol. Exp. Ther. 268, 1597-1604.